Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1996-10-07
1998-11-17
Witz, Jean C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
A01N 6500
Patent
active
058372520
ABSTRACT:
A nontoxic, therapeutic agent having pharmacological activity comprising concentrated extract of Larrea tridentata plant material and ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamin E is made by a process in which the plant material is extracted using an organic solvent, preferably acetone, and is then saturated with one of the listed reducing agents acid to reduce the toxic NDGA quinone, which naturally occurs in the plant material, to NDGA itself. Additional amounts of ascorbic acid, an ascorbic acid ester, an ascorbic acid salt, butylated hydroxyanisole, butylated hydroxytoluene, hydrogen sulfide, hypophosphorous acid, monothioglycerol, potassium bisulfite, propyl gallate, sodium bisulfite, sodium hydrosulfite, sodium thiosulfate, sulfur dioxide, sulfurous acid, a tocopherol, or vitamn E may be added to the extract to inhibit the natural oxidation of the NDGA into the toxic NDGA quinone in vivo, or during processing or storage. The resulting extract is useful in the treatment of viral diseases caused by viruses from the Herpesviridae family or viruses which require the Sp1 class of proteins to initiate viral replications. The resulting compound can also be used as an anti-inflammatory when the inflaatory diseases are mediated by the effects of leukotrienes. The listed reducing agents can also be used to stabilize NDGA as a therapeutic agent or a food additive.
REFERENCES:
patent: 2373192 (1945-04-01), Lauer
patent: 2382475 (1945-08-01), Gisvold
patent: 2644822 (1953-07-01), Pearl
patent: 4765927 (1988-08-01), Nomura et al.
patent: 4774229 (1988-09-01), Jordan
patent: 4880637 (1989-11-01), Jordan
patent: 5276060 (1994-01-01), Neiss et al.
Timmermann "Practical uses of Larrea,' in Creosote Bush: Biology and Chemistry of Larrea in the New World Deserts," Mabry et al. eds. (1977) (Dowden, Hutchison and Ross: Pennsylvania) pp. 252-276.
Tierra, L., "Chapparal," The Herbs of Life: Health and Healing Using Western and Chinese Techniques, pp. 561, 180-181 (1992).
Crellin, J.K. et al., "Chapparal," Herbal Medicines Past and Present II: A Reference Guide to Medicinal Plants, pp. 150-151 (1990).
Sakakibara, et al., Flavonoid Methyl Esters on the External Leaf Surface of Larrea Tridentata and L. Divaricata, 1976, pp. 727-731.
Obermeyer, et al., Chemical Studies of Phytoestrogens and Related Compounds in Dietary Supplements: Flax and Chaparral, 1995, pp. 6-10 vol. 208.
Phytochemistry vol. 23(6) Donald MacRae, et al., Biological Activities of Lignans, 1984, pp. 1207-1220.
Proc. Natl. Acad. Sci. USA vol. 92, Gnabre et al., Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans, 1995, pp. 11239-11243.
Gnabre et al., Characterization of Anti-HIV Lignans from Larrea tridentata, 1995, pp. 12203-12210, Tetrahedron vol. 51(4).
Gnabre et al., Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography, 1996, pp. 353-364 J. Chromatography vol. 719.
Amer. Soc. Hematol. vol. 88(2) Nador et al., Primary Effusion Lymphoma: A Distinct Clinicopathologic Entity Associated With the Kaposi's Sarcoma--Associated Herpes Virus, 1996, pp. 645-656.
The Philadelphia Inquirer Crenson, Kaposi's Sarcoma is tied to herpes, Jul. 31, 1996, p. A4.
Altman, Aids Cancer Said to Have Viral Source: Breakthrough Seen in Kaposi's Sarcoma, Feb. 1, 1995, p. A22 The New York Times.
Critchfield et al., Inhibition of HIV Activation in Latently Infected Cells by Flavonoid Compounds in AIDS Research and Human Retroviruses, 1996, pp. 39-46 vol. 12(1).
Amer. College Phys. vol. 121 Henderson, The Role of Leukotrienes in Inflammation, 1994, pp. 684-697.
Israel et al., Effect of Treatment With Zileuton, a 5-Lipoxygenase Inhibitor, in Patients With Asthma, 196, pp. 932-936 JAMA vol. 275(12).
Gordon, The Microbicical Potential of Various Creosotebush (Larrea Tridentata) Extracts, 1987, pp. 83-85 vol. 21, J. Arizona--Nevada Acad. Sci.
Clark W. Dennis
DeBoer Kenneth Frank
Sinnott Robert A.
Benson David K.
Hanley Susan
Larreacorp, Ltd.
Nichols Steven L.
Witz Jean C.
LandOfFree
Nontoxic extract of Larrea tridentata and method of making same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nontoxic extract of Larrea tridentata and method of making same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nontoxic extract of Larrea tridentata and method of making same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-881451